Tag: anetumab ravtansine
Bayer antibody-drug conjulate (ADC) misses in phase 2 mesothelioma trial
Bayer's antibody-drug conjulate (ADC) anetumab ravtansine has failed to show improvements in the survival rates of mesothelioma patients. Stock prices of Bayer's collaborators ImmunoGen...
